Investasi
Fitur
BiayaKeamanan
Akademi
Lainnya
Pluang+

Bandingkan Harga & Kinerja BFI Finance Indonesia Tbk (BFIN) vs Dharma Polimetal Tbk. (DRMA)

BFI Finance Indonesia TbkTrading
Dharma Polimetal Tbk.Trading

Kinerja harga (24 Jam Terakhir)

Statistik utama

Perbedaan BFI Finance Indonesia Tbk dan Dharma Polimetal Tbk.: BFI Finance Indonesia Tbk diperdagangkan di Rp900 (kapitalisasi pasar 13,76 T, volume 24 jam 18,11 jt), sedangkan Dharma Polimetal Tbk. diperdagangkan di Rp985 (kapitalisasi pasar 4,64 T, volume 24 jam 157 rb). Perbedaan utamanya: BFI Finance Indonesia Tbk jauh lebih besar — sekitar 3× kapitalisasi pasar Dharma Polimetal Tbk., dan BFI Finance Indonesia Tbk lebih aktif diperdagangkan (18,11 jt vs 157 rb). Mana yang lebih baik tergantung tujuan investasimu.

BFINDRMA
Kapitalisasi Pasar
13,76 T4,64 T
Volume
18,11 jt157 rb
Lot
181,1 rb1,57 rb
Perputaran
16,34 M154,75 jt
Harga Rata-rata
902,08985,68
Nilai Transaksi
16,34 M154,75 jt
Harga Ekuilibrium Indikatif
910985
Volume Ekuilibrium Indikatif
19454,6 rb

Perbandingan imbal hasil

Imbal hasil berjalan pada periode standar

Berita terkini

Berita terbaru kedua aset

BFIN
Lihat detail
DRMA
Lihat detail

Tentang BFI Finance Indonesia Tbk

PT BFI Finance Indonesia Tbk (the Company) formerly PT. Bunas Finance Indonesia Tbk (the Company) was established as PT Manufacturers Hanover Leasing Indonesia on April 7, 1982 based on Notarial deed No. 57 of Kartini Muljadi, S.H., Notary in Jakarta. Presently, the Company is engaged in leasing, consumer financing and factoring of accounts receivable. And changed to BFI Finance Indonesia on 2001

Selengkapnya di halaman BFIN

Tentang Dharma Polimetal Tbk.

PT Dharma Polimetal Tbk (“the Company”) was established in the Republic of Indonesia on 27 March based on Notarial deed No. 74 of Rukmasanti Hardjasatya, S.H. The Company begin opertions on year 1989 and commenced its commercial activities since 1990. The Company’s Majority shareholder is PT Dharma Inti Anugerah, established in Republic Indonesia on 20 November 2003.

Selengkapnya di halaman DRMA